(Q37402853)

20 August 2017

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma (English)

1 reference

stem cell transplantation

20 August 2017

1 reference

1 reference

6

Stephen H Petersdorf

1 reference

20 August 2017

5

David G Maloney

1 reference

20 August 2017

Brian G Till

1

1 reference

20 August 2017

Theodore A Gooley

2

1 reference

20 August 2017

Nathan Crawford

3

1 reference

20 August 2017

Ajay K Gopal

4

1 reference

20 August 2017

John M Pagel

7

1 reference

20 August 2017

Leona Holmberg

8

1 reference

20 August 2017

William Bensinger

9

1 reference

20 August 2017

Oliver W Press

10

1 reference

20 August 2017

1 June 2008

1 reference

20 August 2017

1 reference

20 August 2017

49

1 reference

20 August 2017

6

1 reference

20 August 2017

1062-1073

1 reference

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

26 June 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Autologous stem cell transplantation in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Patterns of survival in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923725

Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769072

Autologous hematopoietic stem cell transplantation for mantle cell lymphoma

2 October 2018

1 reference

12 December 2020

The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients

1 reference

12 December 2020

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

1 reference

12 December 2020

Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma

1 reference

12 December 2020

Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma

1 reference

12 December 2020

Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients

1 reference

12 December 2020

Hematopoietic stem cell transplantation in mantle cell lymphoma

1 reference

12 December 2020

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

1 reference

12 December 2020

10.1080/10428190801923725

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

18452065

1 reference